Short answer
CRISPR Therapeutics AG (CRSP) filed its Q1 2026 10-Q quarterly report on May 4, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $1M (up 68.6% year over year) with net income of −$123M.
Q1 2026 key financials · XBRL
- Revenue
- $1M
- +68.6% YoY
- Net income
- −$123M
- +9.6% YoY
- Operating margin
- -8933.3%
- EPS (diluted)
- −$1.28
- +19.0% YoY
Source: XBRL data from the CRISPR Therapeutics AG (CRSP) Q1 2026 10-Q on SEC EDGAR. USD.
CRISPR Therapeutics AG Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1.458M, up $593K YoY, driven by $1.000M collaboration revenue
- Net loss $122.931M vs $135.996M YoY, with operating loss $130.248M vs $148.424M
- Collaboration expense $45.949M, down $11.560M, reflecting increased CASGEVY revenue share
- Cash, equivalents and marketable securities $2.442B at March 31, 2026, including $305.2M outside the U.S
- $600M convertible notes issued at effective 1.7308% coupon, funding continued losses and development costs
Risk Factors
- New 2031 convertible senior notes evidenced by March 16, 2026 indenture
- No officer or director trading-arrangement adoptions, modifications, or terminations during three months ended March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CRISPR Therapeutics AG quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.